WLOX- June 6
Federal regulators voted Thursday to give phone companies the right to block unwanted calls without getting customers' permission first. A hospital in Florida, the Moffitt Cancer Center, received 6,600 calls over 90 days faked to look as though they were coming from inside the hospital, diverting 65 hours of staff time from patient care.
Associated Press – June 6
New technology should help fight the problem, but the government must force carriers to implement it, said Dave Summitt, Moffitt's cybersecurity executive.
"We can't do it by ourselves," he said. "We need help."
Bay News 9 – June 6
Moffitt Cancer Center chief security officer has been tracking this and said Moffitt received 6,600 nuisance calls over 90 days.
WTSP – June 5
Doug Janousek will alter the course of his life with a rare, drastic preventative surgery at Moffitt Cancer Center.
Altoona Mirror – June 5
A hospital in Florida, the Moffitt Cancer Center, received 6,600 calls over 90 days faked to look as though they were coming from inside the hospital, diverting 65 hours of staff time from patient care.
Isreal 21 c – June 5
SpacePharma (Herzliya, Israel) and CadW Therapeutics/Moffitt Cancer Center (Tampa, Florida), which are developing a microfluidics Lab-On-A-Chip that analyzes stress and DNA damage/responses during space flight.
MedPage Today – June 5
Said Heather Sook Han, MD, research director in the Department of Breast Oncology at Moffitt Cancer Center in Tampa, Florida: "You can't really say that one medication is better than the other because of the efficacy data. The main difference between them at this point is in terms of toxicity. And that may be how we consider using these medications on certain patients."
Medcity News – June 3
The leukemia expert, the Moffitt Cancer Center’s Dr. Bijal Shah, added that about 42 percent of patients in a trial of a CD19-directed CAR-T therapy for acute lymphoblastic leukemia in adults had received prior Blincyto.
Reader’s Digest – June 3
Besides providing excellent treatment, the focus at the Moffitt Cancer Center is supporting both the patients and their families and loved ones.
BusinessWire - June 3
“Anti-PD-1 therapy in oncology has been demonstrated to be a safe and effective therapeutic approach in treating certain cancers and increased lymphocyte infiltration has been associated with improved patient outcomes,” said Rohit K Jain, M.D. M.P.H., principal investigator on the Phase 1b trial and Assistant Member in Moffitt Cancer Center Department of Genitourinary Oncology.
Oakland Press – June 3
Other participating institutions include C.S. Mott Children's Hospital, Children's Hospital of Michigan, Moffitt Cancer Center and Boca Raton Regional Hospital-Florida and the University.
PR Newswire – June 3
Winners of the 2019 “40 Under 40 in Cancer” awards were selected by a panel of judges and include the following: Stephen Rosenberg, MD, Moffitt Cancer Center
Globe Newswire – June 3
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim results of the Phase 1b/2 study of pepinemab in combination with avelumab in non-small cell lung cancer (NSCLC) subjects were reported during a poster session on Saturday, June 1 at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Michael Shafique, M.D., Assistant Professor of Thoracic Oncology at the H. Lee Moffitt Cancer Center and Research Institute and first author of the presentation, presented “Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC” during the Developmental Immunotherapy and Tumor Immunobiology poster session.
Globe Newswire – June 3
“These new data for 5F9 show encouraging clinical activity in a broad population of patients with MDS and AML, who may be unfit for existing therapeutic options or at higher risk for developing rapidly-advancing disease,” said David Sallman, M.D., H. Lee Moffit Cancer Center and Research Institute, an investigator for the clinical trial.
Korea Biomedical Review – June 3
Professor Eric B. Haura from the department of thoracic oncology at the Moffitt Cancer Center and Research Institute in the U.S. also caught the eyes of participants with a bispecific JNJ-372 as a way to overcome resistance for Osimertinib.
Villages Daily Sun – June 2
Dr. Bryan McIver, deputy physician-in-chief at Moffitt Cancer Center, credits shifting thinking in late-stage care with rising late-stage survivorship.
Healio – June 2
“Taking the tumor out of the patient allows us to grow these lymphocytes to a far greater number,” Amod Sarnaik, MD, surgical oncologist with the Melanoma Center of Excellence at Moffitt Cancer Center and lead author of the LN-144 study, told HemOnc Today.
BusinessWire – June 2
Jhanelle Gray, MD, Director of Clinical Research in the Thoracic Oncology Department at Moffitt Cancer Center in Tampa, Florida, and an investigator in the PACIFIC trial, said: “In the past, patients with unresectable, Stage III non-small cell lung cancer faced five-year survival rates of only 15 to 30%.
MedCity News – June 1
“Going down to [1 million cells], we weren’t seeing MRD positivity, so it’s very, very encouraging,” study investigator Dr. Bijal Shah, a leukemia and lymphoma specialist at the Moffitt Cancer Center in Tampa, Florida, who presented the data, said in an interview at the ASCO meeting.
BusinessWire – June 1
“Adults with relapsed or refractory ALL represent an extremely difficult-to-treat patient population,” said Bijal Shah, MD, ZUMA-3 investigator and medical oncologist, Moffitt Cancer Center, Tampa, Florida.
Neighborhood News – June 1
On May 21, AHWC and the Moffitt Cancer Center officially broke ground on a new outpatient center to serve cancer patients as part of a new medical office building on the AHWC campus.
OncLive – June 1
JNJ-61186372 elicited a response rate in 30% of 108 participants with diverse primary and secondary EGFR mutations who received the therapy in doses ranging from 700 mg to 1400 mg, said Haura, a senior member in the Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute
US News and World Report – May 31
Women need to understand that not every palpable lump in the breast is an issue. However, it’s important when they notice anything to seek an evaluation by a health care provider who can discern the difference,” says Dr. Susan Hoover, surgical oncologist specializing in breast cancer at the Moffitt Cancer Center Department of Breast Oncology.
TC Palm – May 31
“We saw a specialist in Gainesville, went to Moffitt (Cancer Center) in Tampa, and by the time it was diagnosed, it was very advanced,” said Arango, 60.
Boca Beacon – May 31
With great support from their sponsors and contributors, and in just eight short years, Boca Grande Charities, Inc. has now raised more than $225,000 for institutions and programs such as Moffitt Cancer Center, All Children’s Hospital, The Englewood Community Care Clinic, The Island School, Lemon Bay Conservancy, the Charlotte County School System’s S.T.E.M Camp program, EasterSeals of Southwest Florida and the Dee Wheeler Scholarship Fund.
Targeted Oncology – May 24
In addition, Komrokji, a senior member of the Malignant Hematology and Experimental Therapeutics Program and head of the Leukemia and Myelodysplastic Syndrome Section and vice chair of the Malignant Hematology Department at the Moffitt Cancer Center, discussed treatment options based on the case scenario of a patient with myelofibrosis (MF).
Healio – May 24
In this installment of In Practice, Julio C. Chavez, MD, assistant member in the lymphoma section of the department of malignant hematology at Moffitt Cancer Center, will discuss the challenges and best practices when preparing patients and their community oncologist for departure from the cell therapy clinic and back to the community setting.
STAT – May 24
A longtime lobbyist in Tallahassee, who I don’t even know but who follows me on Twitter — I tweet often about cancer and also health care topics that I’m writing about — he knew the founder of Moffitt Cancer Center, H. Lee Moffitt, and called him.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.